Belgium’s food safety agency AFSCA-FAVV has ordered Ferrero to suspend production at its plant in Arlon, Belgium due to a link that has been confirmed between more than a hundred cases of salmonella and Kinder chocolate production.
According to AFSCA-FAVV, the decision to temporarily close the plant was taken after finding the information from Ferrero to be incomplete.
Ferrero, the Italian chocolate giant, canceled a number of its Kinder products last week owing to salmonella concerns.
The tainted chocolate was made at Ferrero's Arlon plant, where salmonella was discovered in a filter in December.
According to the Food Standards Agency in the United Kingdom, at least 63 instances of salmonella have been connected to Kinder products, with the majority of the cases occurring in children under the age of five.
Other countries affected by recalls included the US and several European states.
Ferrero acknowledged internal inefficiencies that caused delays in retrieving and sharing information promptly.
Ferrero revealed that the plant would only reopen once certified by the authorities.


China’s ‘Lipstick King’ Says AI Won’t Replace Livestream Hosts
Australia Unemployment Hits Five-Year High Despite Strong Jobs Growth
SpaceXAI to Double Nvidia Chips at Colossus 2 by Year-End
AMD Hits $1 Trillion as BofA Raises Price Target to $720
US 10-Year Treasury Yield at 6% Emerges as New Market Risk Threshold
Trump Signs Order to Cut Routine Childhood Vaccines
European Stocks Fall as Bond Yields and Geopolitical Risks Weigh
Asian Stocks Fall as Surging Bond Yields Rattle Markets
Tesla Semi Rollout Begins at Nevada Factory
FDA Approves Mirum’s Atebrioz for Rare Bone Disorder FOP
Airbus Finds A321neo Fuselage Quality Issue
Asian Currencies Mixed as Dollar Holds Near Two-Month High
3 clinical-grade skincare creams you really shouldn’t buy online
Asian Stocks Fall as Bond Yields Surge Ahead of Trump-Xi Summit
Suzuki Targets Faster Car Development to Keep Pace With Chinese Rivals
BMW 2028 Margin Target Could Fall Below Consensus, UBS Says
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 



